Hohenester S, Beuers U
Liver Center Munich, Department of Medicine II, University Hospital, LMU Munich, Munich, Deutschland.
Department of Gastroenterology and Hepatology and Tytgat Institute for Liver and Intestinal Research, Academic Medical Center, G4-216, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, Niederlande.
Internist (Berl). 2017 Aug;58(8):805-825. doi: 10.1007/s00108-017-0287-z.
In the long-term course chronic cholestasis regularly leads to fibrotic restructuring and ultimately to functional failure of the liver, independent of the cause. Cholestatic diseases are often clinically asymptomatic. In order to avoid progression, early diagnosis of the underlying disease and a targeted therapy are therefore decisive. The differential diagnoses of chronic cholestasis are broad; therefore, algorithms are of assistance in the diagnostic work-up. A better understanding of the pathogenesis is now leading to the development of new therapeutic agents in addition to ursodeoxycholic acid, which has long been known for its anticholestatic effects. Obeticholic acid and, in the near future, bezafibrate are therapeutic options. The possibilities for genetic diagnostics of unclear cholestasis syndromes improve the understanding of the pathogenesis of many diseases and are being introduced increasingly earlier into the clinical routine.
在长期病程中,慢性胆汁淤积通常会导致肝纤维化重构,并最终导致肝功能衰竭,无论其病因如何。胆汁淤积性疾病在临床上通常无症状。为避免病情进展,因此对潜在疾病的早期诊断和靶向治疗至关重要。慢性胆汁淤积的鉴别诊断范围广泛;因此,算法有助于诊断检查。除了长期以来以其抗胆汁淤积作用而闻名的熊去氧胆酸外,对发病机制的更好理解现在正导致新治疗药物的开发。奥贝胆酸以及在不久的将来的苯扎贝特都是治疗选择。不明胆汁淤积综合征的基因诊断可能性提高了对许多疾病发病机制的理解,并越来越早地被引入临床常规。